Epidemiology and Genomics Research Funding Opportunities

The Epidemiology and Genomics Research Program (EGRP) provides funding support for research in human populations to understand the causes of cancer and related outcomes. EGRP is the largest funder of cancer epidemiology grants nationally and worldwide. In addition to supporting investigator-initiated research grants, EGRP sponsors or co-sponsors a variety of targeted funding opportunity announcements (FOAs). Here we provide a listing of funding opportunities that are currently accepting applications. Please visit this page regularly as new funding opportunities are added upon approval by NCI.

FOAs Sponsored/Co-Sponsored by EGRP

NOTE: The following table lists the newest FOAs at the top of the table.

FOAs Sponsored/Co-Sponsored
by EGRP
Announcement Number
(Grant Mechanism)
Submission Dates Expiration Date
Ethical, Legal, Social Implications of Human Genome Research
Summary Details
PA-14-276External Web Site Policy (R01) R01: Feb. 5, June 5, and Oct. 5 Sept. 8, 2017

Summary:
This PA invites multidisciplinary research applications that identify, examine, and address the ethical, legal, and social implications (ELSI) of advances in genomic research and technology for individuals, families, communities, and society more broadly. NCI is interested in empirical research that focuses on the ethical, legal, and social issues related to heritable cancer syndromes. Study of the psychosocial and behavioral impact on affected individuals, their families, and populations and research that takes into consideration the perpsectives of diverse racial, ethnic, and socioeconomic backgrounds, as well as children, older adults, and people with disabilities, is highly desirable. The ultimate goal of this research will be to improve outcomes related to the diagnosis of heritable cancer syndromes. The National Human Genome Research Institute (NHGRI) is the lead sponsor of the PA; several other NIH Institutes also are cosponsors. For more information: PA-14-276External Web Site Policy (R01).

Contact: Charlisse Caga-anan, J.D., Program Director, Host Susceptibility Factors Branch, e-mail: cagaananef@mail.nih.gov

Core Infrastructure and Methodological Research for Cancer Epidemiology
Summary Details
PAR-14-160External Web Site Policy (U01) July 8 and Nov. 10, 2014
Mar. 11, July 8, and Nov. 10, 2015
Mar. 11, July 8, and Nov. 10, 2016
Mar. 10, 2017
Mar. 11, 2017

Summary:
This PAR invites grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This PAR will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of NCI’s Division of Cancer Control and Population Sciences (DCCPS). For more information: PAR-14-160External Web Site Policy (U01) and FAQs

Contact: Joanne Elena, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: wattersj@mail.nih.gov

Genomic Resource Grants for Community Resource Projects
Summary Details
PAR-14-191External Web Site Policy (U41) Jan. 25, May 25, and Sept. 25, 2015
Jan. 25, May 25, and Sept. 25, 2016
Jan. 25, 2017
Jan. 26, 2017

Summary:
Awards under this FOA will support the development and distribution of genomic resources that will be available to and valuable for the broad research community, using cost-effective approaches. Such resources include (but are not limited to) informatics resources (such as human and model organism databases, ontologies, and coordinated sets of analysis tools), comprehensive identification and collections of genomic features (such as structural variants or functional genomic elements), and standard data types produced for central sets of samples (such as 1000 Genomes or GTEx samples). The National Human Genome Research Institute (NHGRI) is the lead sponsor of the FOA and NCI is a co-sponsor. For more information: PAR-14-191External Web Site Policy (U41).

Contact:: Leah Mechanic, Ph.D., M.P.H., Program Director, Host Susceptibility Factors Branch, e-mail: mechanil@mail.nih.gov

Research on Malignancies in the Context of HIV/AIDS
Summary Details
PAR-13-377External Web Site Policy (R01); see also PAR-13-378External Web Site Policy (R21) R01: Jan. 7, May 7, and Sept. 7
R21: Jan. 7, May 7, and Sept. 7
Sept. 8, 2016

Summary:
The purpose of these PAs is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). These PAs seek to encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both AIDS-defining and non-AIDS-defining malignancies in diverse populations.

These PAs invite research efforts that will: (1) provide information on the clinical outcomes of such cancers in the HIV-infected population; and (2) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Office of AIDS Malignancy Program, with the National Institute of Dental and Craniofacial Research (NIDCR). For more information: PAR-13-377External Web Site Policy (R01); PAR-13-378External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Methods and Technologies Branch, e-mail: starksv@mail.nih.gov

Mechanistic Insights from Birth Cohorts
Summary Details
PAR-13-109External Web Site Policy (R01); see also NOT-CA-13-002External Web Site Policy June 5, Oct. 5, 2013
Feb. 5, June 5, Oct. 5, 2014
Feb. 5, June 5, Oct. 5, 2015
Feb. 5, 2016
May 8, 2016

Summary:
This FOA is intended to support novel research on how prenatal exposures contribute to the etiology of chronic diseases and health conditions later in life. Little is known about the mechanisms by which such prenatal exposures lead to diabetes or obesity, renal, pulmonary, or cardiovascular or hematologic disease, neurodevelopmental disorders, reproductive health (i.e. fertility), or cancer. The goal of this FOA is to stimulate research by leveraging existing birth cohorts to address targeted mechanistic questions regarding the normal and abnormal developmental origins of organ systems and/or diseases of interest to the participating NIH Institutes and Centers. For more information: PAR-13-109External Web Site Policy and NOT-CA-13-002External Web Site Policy.

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Modifiable Risk Factors Branch; e-mail: mahabir@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-286External Web Site Policy (R01, R37) R01 and R37:
Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR encourages revision applications (formerly called "competing revisions") from currently funded R01s and R37s with at least one year left at the estimated time of award. Early-stage development is defined as the initial development or significant modification of existing tools for new applications. For more information: PAR-12-286External Web Site Policy (R01, R37)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Advanced Development of Informatics Technology
Summary Details
PAR-12-287External Web Site Policy (U24) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites U24s for advanced development and enhancement of emerging informatics technologies, which are ones that have passed the initial prototyping and pilot development stage, demonstrated potential to have a significant and broader impact, have compelling reasons for further improvement and enhancement, and have not been widely adopted in the cancer research field. For more information: PAR-12-287External Web Site Policy (U24)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Early-Stage Development of Informatics Technology
Summary Details
PAR-12-288External Web Site Policy (U01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites U01s and focuses on early-stage development from prototyping to hardening and adaption. For more information: PAR-12-288External Web Site Policy (U01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-289External Web Site Policy (U01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR solicits revisions (formerly called "competing revisions") from currently funded U01s with at least one year left at the estimated time of award. For more information: PAR-12-289External Web Site Policy (U01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-290External Web Site Policy (P01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites revisions (formerly called "competing revisions") from currently funded P01s with at least one year left at the estimated time of award. For more information: PAR-12-290External Web Site Policy (P01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers
Summary Details
RFA-14-027External Web Site Policy (U01) April 2, 2015 April 3, 2015

Summary:
This RFA invites applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center
Summary Details
RFA-DK-14-028External Web Site Policy (U01) April 2, 2015 April 3, 2015

Summary:
This RFA invites applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.

The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.

To achieve the goal of a comprehensive characterization of evolving chronic pancreatitis and pancreatic cancer, the Coordinating and Data Management Center (CDMC) will take on the administrative and data collection/analysis functions and will be responsible for the conduct of all of the ongoing and future studies of the CCs. In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of bio-specimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection.

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Coordinating Center for the Breast Cancer and the Environment Research Program
Summary Details
RFA-ES-14-011External Web Site Policy (U01) Jan. 28, 2015 Jan. 29, 2015

Summary:
This funding opportunity will support a Coordinating Center, which will provide intellectual leadership as well as logistic support for the BCERP Consortium. The primary roles of the Coordinating Center will be to identify opportunities for cross-BCERP collaborations, extend transdisciplinary activities of the BCERP Consortium, assist in disseminating BCERP research findings, and facilitate an internal evaluation of the Consortium.

Contact: Gary L. Ellison, Ph.D., M.P.H., Acting Chief, Modifiable Risk Factors Branch, e-mail: ellisong@mail.nih.gov

Environmental Influences during Windows of Susceptibility in Breast Cancer Risk
Summary Details
RFA-ES-14-012External Web Site Policy (U01) Jan. 28, 2015 Jan. 29, 2015

Summary:
This funding opportunity will support transdisciplinary research projects that address one or more potential windows of susceptibility and facilitates the integration of experimental model and human studies to accelerate understanding of the contribution of environmental factors to breast cancer risk, the underlying mechanisms, and potential prevention strategies. Applications must also include community-academic partnerships with defined community engagement activities.

Contact: Gary L. Ellison, Ph.D., M.P.H., Acting Chief, Modifiable Risk Factors Branch, e-mail: ellisong@mail.nih.gov

Pilot Studies in Pancreatic Cancer
Summary Details
PA-11-298External Web Site Policy (R03)
PA-11-297External Web Site Policy (R21)
R03 and R21:
Feb. 16, June 16, and Oct. 16
Jan. 5, 2015

Summary:
These trans-NCI PAs are to promote innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. Inquiries about cancer control, epidemiology, and survivorship research proposals are handled by EGRP. For more information: PA-11-298External Web Site Policy (R03); PA-11-297External Web Site Policy (R21)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov


Other funding opportunities of interest not sponsored by EGRP


Subscribe to EGRP's monthly Cancer Epidemiology E-News to receive details about recent NIH FOAs and Notices of Intent to publish an FOA, as well as relevant funding opportunities from other organizations. View current and past issues and subscribe.

Return to Top